Environmental, Social And Governance Report

Overview

The report describes Hengrui Pharma's fifth ESG reporting year, covering its subsidiaries and a formal double materiality assessment that identified 26 material topics. It reports Scope 1, Scope 2 and Scope 3 emissions, a 10% Scope 1 and 2 emissions-intensity reduction target by 2030, and expanded Scope 3 accounting. The company reports 20,602 employees, 100% training coverage and 45.6% female workforce representation. It also highlights equitable pricing, expanded reimbursement-list access and healthcare-capacity initiatives in emerging markets.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2025
Period: 1 January 2025 – 31 December 2025
Publication date: 25 March 2026
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level

Materiality

Assessment
Basis
Matrix

Assurance

Scope
Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services

Overview